Mostrando 2 resultados de: 2
Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof-of-Principle Issues from a Randomized Controlled Study
ArticleAbstract: Background: Several pieces of evidence have shown the neurotrophic effect of erythropoietin (EPO) anPalabras claves:Clinical trial, erythropoietin, human-recombinant erythropoietin, spinocerebellar ataxia type 2Autores:Almaguer Gotay D., Amaro-González D., Aymed-García J., Batista-Nuñez M., Canales-Ochoa N., Carmen Elena Viada, Columbié Ximelis J., Crombet-Ramos T., Estupiñán Rodriguez A., García-García I., García-Rodriguez J.C., Hernández Casaña P., Jiménez-Rodríguez D., Labrada Aguilera P.E., Medrano Montero J., Ortega-Sanchez R., Padrón-Estupiñan M.d.C., Peña Acosta A., Rodríguez-Labrada R., Rodriguez-Obaya T., Santos-Morales O., Silva Ricardo Y., Torres Vega R., Tribin Rivero K., Valenzuela-Silva C.M., Valle Cabrera R., Vazquez-Mojena Y., Velazquez-Perez L.Fuentes:scopusNasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: A randomized, parallel, open-label safety study
ArticleAbstract: Background: Delivery of therapeutic agents as erythropoietin (EPO) into Central Nervous System throuPalabras claves:Healthy volunteers, Hematopoietic activity, neurodegenerative diseases, NeuroEPO, Non-hematopoietic recombinant erythropoietin, safety, strokeAutores:Alfonso-Muñoz E., Amaro-González D., Carmen Elena Viada, Díaz-Machado A., Festary-Casanovas T., García-García I., González-Delgado C.A., Jiménez-Rodríguez D., Pérez-Rodríguez S., Piedra-Sierra P., Pomares-Iturralde Y., Santos-Morales O.Fuentes:scopus